Search

Your search keyword '"Schuitemaker, Hanneke"' showing total 14 results
Start Over Author "Schuitemaker, Hanneke" Journal vaccine
14 results on '"Schuitemaker, Hanneke"'

6. Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials

Author

Sadoff, Jerald, primary, Le Gars, Mathieu, additional, Brandenburg, Boerries, additional, Cárdenas, Vicky, additional, Shukarev, Georgi, additional, Vaissiere, Nathalie, additional, Heerwegh, Dirk, additional, Truyers, Carla, additional, de Groot, Anne Marit, additional, Jongeneelen, Mandy, additional, Kaszas, Krisztian, additional, Tolboom, Jeroen, additional, Scheper, Gert, additional, Hendriks, Jenny, additional, Ruiz-Guiñazú, Javier, additional, Struyf, Frank, additional, Van Hoof, Johan, additional, Douoguih, Macaya, additional, and Schuitemaker, Hanneke, additional

Published
2022
Full Text
View/download PDF

7. Immunogenicity and protective efficacy of adenoviral and subunit RSV vaccines based on stabilized prefusion F protein in pre-clinical models

Author

Saeland, Eirikur, primary, van der Fits, Leslie, additional, Bolder, Renske, additional, Heemskerk-van der Meer, Marjolein, additional, Drijver, Joke, additional, van Polanen, Yolinda, additional, Vaneman, Cornelis, additional, Tettero, Lisanne, additional, Serroyen, Jan, additional, Schuitemaker, Hanneke, additional, Callendret, Benoit, additional, Langedijk, Johannes P.M., additional, and Zahn, Roland C., additional

Published
2022
Full Text
View/download PDF

8. Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment

Author

Custers, Jerome, primary, Kim, Denny, additional, Leyssen, Maarten, additional, Gurwith, Marc, additional, Tomaka, Frank, additional, Robertson, James, additional, Heijnen, Esther, additional, Condit, Richard, additional, Shukarev, Georgi, additional, Heerwegh, Dirk, additional, van Heesbeen, Roy, additional, Schuitemaker, Hanneke, additional, Douoguih, Macaya, additional, Evans, Eric, additional, Smith, Emily R., additional, and Chen, Robert T., additional

Published
2021
Full Text
View/download PDF

12. PER.C6® cells as a serum-free suspension cell platform for the production of high titer poliovirus: A potential low cost of goods option for world supply of inactivated poliovirus vaccine

Author

Sanders, Barbara P., primary, Edo-Matas, Diana, additional, Custers, Jerome H.H.V., additional, Koldijk, Martin H., additional, Klaren, Vincent, additional, Turk, Marije, additional, Luitjens, Alfred, additional, Bakker, Wilfried A.M., additional, Uytdehaag, Fons, additional, Goudsmit, Jaap, additional, Lewis, John A., additional, and Schuitemaker, Hanneke, additional

Published
2013
Full Text
View/download PDF

14. PER.C6® cells as a serum-free suspension cell platform for the production of high titer poliovirus: A potential low cost of goods option for world supply of inactivated poliovirus vaccine

Author

Sanders, Barbara P., Edo-Matas, Diana, Custers, Jerome H.H.V., Koldijk, Martin H., Klaren, Vincent, Turk, Marije, Luitjens, Alfred, Bakker, Wilfried A.M., Uytdehaag, Fons, Goudsmit, Jaap, Lewis, John A., and Schuitemaker, Hanneke

Subjects
*SERUM-free culture media, *POLIOVIRUS, *VIRAL vaccines, *ORAL poliomyelitis vaccines, *SEROTYPES, *CELL culture, *MICROBIAL virulence
Abstract

Abstract: There are two highly efficacious poliovirus vaccines: Sabin''s live-attenuated oral polio vaccine (OPV) and Salk''s inactivated polio vaccine (IPV). OPV can be made at low costs per dose and is easily administrated. However, the major drawback is the frequent reversion of the OPV vaccine strains to virulent poliovirus strains which can result in Vaccine Associated Paralytic Poliomyelitis (VAPP) in vaccinees. Furthermore, some OPV revertants with high transmissibility can circulate in the population as circulating Vaccine Derived Polioviruses (cVDPVs). IPV does not convey VAPP and cVDPVs but the high costs per dose and insufficient supply have rendered IPV an unfavorable option for low and middle-income countries. Here, we explored whether the human PER.C6® cell-line, which has the unique capability to grow at high density in suspension, under serum-free conditions, could be used as a platform for high yield production of poliovirus. PER.C6® cells supported replication of all three poliovirus serotypes with virus titers ranging from 9.4log10 to 11.1log10 TCID50/ml irrespective of the volume scale (10ml in shaker flasks to 2L in bioreactors). This production yield was 10–30 fold higher than in Vero cell cultures performed here, and even 100-fold higher than what has been reported for Vero cell cultures in literature [38]. In agreement, the D-antigen content per volume PER.C6®-derived poliovirus was on average 30-fold higher than Vero-derived poliovirus. Interestingly, PER.C6® cells produced on average 2.5-fold more D-antigen units per cell than Vero cells. Based on our findings, we are exploring PER.C6® as an interesting platform for large-scale production of poliovirus at low costs, potentially providing the basis for global supply of an affordable IPV. [Copyright &y& Elsevier]

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results